Biotech IV Monitor

SION — Sionna Therapeutics Inc.

$2.1B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Sionna Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$2.1B
Cash & investments$250M~8 quarters at last loss rate
Recent 8-K filings1latest 2026-11-10

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2 SION-719
Cystic Fibrosis (CF) · NCT07108153
June 2026
Primary data collected

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2a SION-719
Cystic Fibrosis
July 2026
Ongoing

Cash position

Sionna Therapeutics Inc. reported $250M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $32M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-10

Companies working on similar indications

Discussion

No messages yet. If you follow SION, you can start the conversation.
Track SION in real time
See live implied volatility for SION and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on SION
Contact — questions or corrections about SION: dukeupt@gmail.com